QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 03:05:25 2024-03-28 pm EDT 5-day change 1st Jan Change
48.24 USD -0.04% Intraday chart for QuidelOrtho Corporation +2.04% -34.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
QuidelOrtho Receives Canada's Approval for Triage PLGF Test to Detect Pregnancy Complications MT
Transcript : QuidelOrtho Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 04:00 PM
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
QuidelOrtho Shares Decline Following UBS Downgrade MT
UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70 MT
Sector Update: Health Care Stocks Mixed in Late Afternoon MT
Sector Update: Health Care MT
QuidelOrtho Terminates CEO Douglas Bryant, Postpones Investor Day MT
QuidelOrtho Corporation Announces CEO Changes CI
QuidelOrtho Corporation Announces Changes in Executive Leadership, Effective from February 21, 2024 CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Top Midday Decliners MT
QuidelOrtho Shares Slump After Analysts Downgrade Stock Following Lower Q4 Results MT
William Blair Downgrades QuidelOrtho to Market Perform From Outperform MT
Citigroup Adjusts Price Target on QuidelOrtho to $50 From $72, Maintains Neutral Rating MT
Craig-Hallum Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $50 From $158 MT
Raymond James Downgrades QuidelOrtho to Outperform From Strong Buy, Cuts Price Target to $76 From $100 MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
JPMorgan Downgrades QuidelOrtho to Underweight From Neutral, Adjusts Price Target to $37 From $66 MT
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Traders Recover From Inflation Figures Shock MT
RBC Adjusts PT on QuidelOrtho to $81 From $130, Notes Worse-Than-Anticipated COVID Headwinds; Outperform Kept on 'Compelling' Risk/Reward MT
Top Premarket Decliners MT
Chart QuidelOrtho Corporation
More charts
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
48.26 USD
Average target price
56 USD
Spread / Average Target
+16.04%
Consensus
  1. Stock
  2. Equities
  3. Stock QuidelOrtho Corporation - Nasdaq
  4. News QuidelOrtho Corporation
  5. Quidel : Receives FDA Emergency Use Authorization for Sophia Q Testing Device